VEGF News and Research

RSS

VEGF is a substance made by cells that stimulates new blood vessel formation. Also called vascular endothelial growth factor.

Study shows how parasitic bacteria cause lesions in the skin and internal organs

Bacteria of the genus Bartonella are parasites that can be transmitted to humans via insect bites and animal scratches, resulting in an infection known as "bartonellosis."

16 Jul 2020

Research sheds light on mysterious COVID-19 related hyperinflammatory shock in children

The ongoing COVID-19 pandemic has cost hundreds of thousands of human lives, besides more than 11 million cases. Caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the disease was initially thought to be more severe in the elderly and those with pre-existing medical conditions. However, it started to manifest in children after the peak of the first wave.

7 Jul 2020

Researchers use nanoparticles to deliver gene therapy for blinding eye disease

In experiments in rats and mice, two Johns Hopkins scientists -; an engineer and an ophthalmologist -; report the successful use of nanoparticles to deliver gene therapy for blinding eye disease.

7 Jul 2020

Markers of vascular damage in COVID-19

A new study by researchers at Yale University and published on the preprint server medRxiv reports on the plasma levels of biomolecules that reflect vascular damage in COVID-19.

2 Jul 2020

Developing lymphatic vessels in zebrafish

When an embryo develops, a wide variety of proteins and enzymes trigger a series of biochemical reactions. The development of the lymphatic vasculature is crucially dependent on one specific protein - the growth factor VEGF-C.

11 Jun 2020

Progression and severity of COVID-19 highly dependant on cytokine changes

A new review paper by the researchers from Spain, published in the journal Cytokine & Growth Factor Reviews, demonstrates how changes in the levels of cytokines and other biomolecules are associated with the presence and more serious prognosis of coronavirus disease (COVID-19).

11 Jun 2020

A faster and easier treatment option to prevent blindness in preterm infants

Babies born prematurely who require treatment to prevent blindness from retinopathy of prematurity (ROP) could be treated with a dose of Avastin (bevacizumab) that is a fraction of the dose commonly used for ROP currently.

23 Apr 2020

Study uncovers cause of blood-vessel leakiness in eye diseases

Scientists have identified a key step in the process that leads to leaky vessels and harmful swelling in eye diseases, according to a new study published today in eLife.

21 Apr 2020

Research suggests potential treatment target to slow lymphoma tumor growth

Researchers at the MDC observe the very early stages of blood vessel development in lymph node tumors.

7 Apr 2020

Novel strategy to stop tumors from developing new blood vessels

Scientists at the National Institutes of Health and other institutions have devised a new strategy to stop tumors from developing the new blood vessels they need to grow.

11 Mar 2020

Missing doctor's visit linked to decreased visual acuity for patients with AMD

Missing a single ophthalmology appointment over a two-year period was associated with decreased visual acuity for patients with macular degeneration -- a leading cause of permanent vision loss in the elderly -- according to a new Penn Medicine study.

6 Feb 2020

Research suggests a new role for neurogenesis

The ability to create new neurons may exist as built-in protection for sensitive brain areas, according to research in mice recently published in JNeurosci.

From Society for Neuroscience 14 Jan 2020

Study may provide novel targetable mechanisms of therapeutic resistance to anti-VEGF therapies

To establish a molecular signature of this resistance in ovarian cancer, the authors developed preclinical tumor models of adaptive resistance to chronic anti-VEGF treatment.

8 Jan 2020

Helper protein exacerbates diabetic macular edema

In a recent study using mice, lab-grown human retinal cells and patient samples, Johns Hopkins Medicine scientists say they found evidence of a new pathway that may contribute to degeneration of the light sensitive tissue at the back of the eye.

27 Nov 2019

Secretome of pleural effusions linked to NSCLC and malignant mesothelioma

Cryopreserved cell-free PE fluid from 101 NSCLC patients, 8 mesothelioma and 13 with benign PE was assayed for a panel of 40 cytokines/chemokines using the Luminex system.

25 Nov 2019

Combination therapy improves survival in patients with hepatocellular carcinoma

Combination therapy with the PD-L1 inhibitor atezolizumab and the VEGF inhibitor bevacizumab significantly improves overall survival and progression-free survival in patients with unresectable hepatocellular carcinoma compared to standard of care, showed results from a phase 3 study reported at the ESMO Asia 2019 Congress.

22 Nov 2019

Study shows importance of targeted antibody treatment for patients with wet macular degeneration

Wet age-related macular degeneration is one of the leading causes of blindness in the U.S. Breakthrough treatments come with a steep price tag and treatment burden for the patient, but a new study suggests their benefits to patient health and society top billions of dollars, or more, if adherence could be improved.

15 Nov 2019

Study: Pleural effusions are linked with NSCLC and malignant mesothelioma

Cryopreserved cell-free PE fluid from 101 NSCLC patients, 8 mesothelioma and 13 with benign PE was assayed for a panel of 40 cytokines/chemokines using the Luminex system.

6 Nov 2019

Researchers identify new kidney cancer subtypes and clues to better diagnosis, treatment

In what is believed to be the most comprehensive molecular characterization to date of the most common - and often treatment-resistant - form of kidney cancer, researchers at Johns Hopkins' departments of pathology and oncology, Johns Hopkins Kimmel Cancer Center, and the Johns Hopkins University School of Medicine report evidence for at least three distinct subtypes of clear cell renal cell carcinoma (ccRCC), along with new revelations about the proteins that define them.

From Johns Hopkins Medicine 31 Oct 2019

New gene therapy for wet age-related macular degeneration is on the horizon

Gene therapy is showing promise for one of the most common causes of blindness. Data presented today shows that six patients with wet age-related macular degeneration have, so far, gone at least six months without the need for continued injections to control a disease that typically requires treatment every four to six weeks.

11 Oct 2019